Pharsight

Dificid generic

Dificid is an antibiotic drug owned by Cubist Pharms Llc. The active ingredient in Dificid is fidaxomicin. It got its first market authorization on 27 May, 2011.

When will Dificid generic be available?

The generic versions of Dificid are likely to be available after 28 November, 2034. This is due to the expiration of its last substance patent, US9808530*PED, titled 'Composition of tiacumicin compounds', that expires on 28 November, 2034.

Dificid uses

Dificid is used for the treatment of clostridioides difficile-associated diarrhea (cdad) in patients from 6 months of age and older. It can also be used for the treatment of microbial infections.

Dificid patent expiration

Dificid has a total of 13 patents, out of which 1 has expired. The patents cover various aspects from its active ingredient Fidaxomicin to its various uses. The last patent of Dificid, 'Composition of tiacumicin compounds' (US9808530*PED), is set to expire on 28 November, 2034. Below are the details of the patents:

Dificid dosage

Want to ask something?